NASDAQ:CASC

(CASC) (CASC) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$10.02
$10.02
50-Day Range
N/A
52-Week Range
$3.18
$10.21
Volume
N/A
Average Volume
1.09 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CASC stock logo

About (CASC) Stock (NASDAQ:CASC)

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

CASC Stock News Headlines

Exposed: 10 CENT Crypto to Explode April 20th?
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…
Exposed: 10 CENT Crypto to Explode April 20th?
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…
Cascade Copper Corp CASC
China plans 100 launches into space
China's deep-space ambition
See More Headlines
Receive CASC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (CASC) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2017
Today
4/26/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CASC
CUSIP
68232410
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Christopher S. Henney Ph.D. (Age 76)
    Chairman of the Board
  • Scott D. Myers (Age 51)
    President, Chief Executive Officer, Director
  • Julia Marie Eastland (Age 51)
    Chief Financial Officer, Vice President - Corporate Development, Secretary
  • Gary W. Christianson (Age 61)
    Chief Operating Officer
  • Scott Peterson Ph.D. (Age 54)
    Chief Scientific Officer
  • Robert W. Azelby (Age 49)
    Director
  • Gwendolyn A. Fyfe M.D. (Age 65)
    Independent Director
  • Steven P. James (Age 58)
    Independent Director
  • Ted W. Love M.D. (Age 58)
    Independent Director
  • Daniel Keith Spiegelman (Age 58)
    Independent Director

CASC Stock Analysis - Frequently Asked Questions

How were (CASC)'s earnings last quarter?

(CASC) (NASDAQ:CASC) announced its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. During the same quarter last year, the company posted ($0.09) earnings per share.

What other stocks do shareholders of (CASC) own?
This page (NASDAQ:CASC) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners